Executive Order 14292 establishes a sweeping prohibition on certain types of biological research deemed dangerous to national security and public health. The order characterizes the Biden Administration's approach to gain-of-function research as having had "insufficient levels of oversight" and being "reckless," particularly regarding federally funded research in China and other countries with limited U.S. oversight. The order frames these research practices as potential existential threats that could lead to "widespread mortality," "impaired public health," and "diminished economic and national security" if left unregulated. It positions these measures as critical course corrections after the COVID-19 pandemic revealed the risks of such research practices.
The order mandates immediate cessation of federal funding for "dangerous gain-of-function research" conducted by foreign entities in "countries of concern" (explicitly naming China) and suspends similar research domestically pending policy review. It directs the Office of Science and Technology Policy (OSTP) to revise or replace existing frameworks within 120 days, specifically targeting the 2024 "United States Government Policy for Oversight of Dual Use Research of Concern" and the "Framework for Nucleic Acid Synthesis Screening." The order further requires development of a strategy within 180 days to govern non-federally funded dangerous research and establishes a public reporting mechanism for research institutions receiving federal funds. Notably, the order provides a detailed seven-part definition of "dangerous gain-of-function research" that includes enhancing pathogenicity, transmissibility, or harmful consequences of agents or toxins.
Implementation responsibilities primarily fall to the OSTP Director, working in coordination with the Office of Management and Budget Director and the Assistant to the President for National Security Affairs. The Secretary of Health and Human Services and heads of other relevant agencies must incorporate strict enforcement mechanisms into all life-science research contracts and grants, including provisions that make compliance with the order material to government payment decisions under the False Claims Act. Violations may result in immediate revocation of federal funding and up to five years of ineligibility for federal life-sciences grants. The order presents these restrictions as balanced against the need to maintain "readiness against biological threats" and "driving global leadership in biotechnology," though the primary emphasis remains on security concerns rather than scientific advancement.